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Abstract
The liver is a unique organ, and first in line, the hepatocytes encounter the potential to proliferate during cell mass loss. This phenomenon
is tightly controlled and resembles in some way the embryonal co-inhabitant cell lineage of the liver, the embryonic hematopoietic system.
Interestingly, both the liver and hematopoietic cell proliferation and growth are controlled by various growth factors and cytokines. IL-6 and
its signaling cascade inside the cells through STAT3 are both significantly important for liver regeneration as well as for hematopoietic cell
proliferation. The process of liver regeneration is very complex and is dependent on the etiology and extent of liver damage and the genetic
background. In this review we will initially describe the clinical relevant condition, portraying a number of available animal models with an
emphasis on the relevance of each one to the human condition of fulminant hepatic failure (FHF). The discussion will then be focused on the
role of cytokines in liver failure and regeneration, and suggest potential new therapeutic modalities for FHF. The recent findings on the role of
IL-6 in liver regeneration and the activity of the designer IL-6/sIL-6R fusion protein, hyper-IL-6, in particular, suggest that this molecule
could significantly enhance liver regeneration in humans, and as such could be a useful treatment for FHF in patients.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Cytokine; Liver; Regeneration; stem cells
1. Introduction
Healthy liver regulates its growth in an exquisite homeo-
static mechanism, maintaining constant tissue mass relative
to levels of metabolic stress in the body. In both small
mammals and humans, throughout the life of the organism,
hepatocytes, the main functional cell of the organ, retain a
remarkable capacity to adjust to changes in metabolic
demand by cell division in the event of a metabolic deficit,
or alternatively, through apoptosis in the event of excess
metabolic capacity. In particular, the sudden loss of tissue
mass, in an otherwise healthy individual, leads to a rapid
and robust response of cellular division involving all of the
mature cell populations of the liver, foremost of which are
the hepatocytes. In the clinic, the precipitous loss of liver
parenchyma is most commonly the result of an acute insult
of viral or chemical origin, and is associated with cata-
strophic consequences resulting from the failure of the organ
to maintain essential metabolic functions.
During the last few years we have obtained substantial
insight from three major research directions in liver biology
that have substantially elucidated the roles of cytokines,
growth factors, their receptors and intracellular signaling
molecules on liver development and regeneration. The first
group of studies has unfolded new findings on the molecular
mechanisms of liver development and differentiation, and
has identified major players in early stages of this process.
These includes fibroblastic growth factor (FGF) as the major
ligand [1], the c-MET (the receptor for hepatic growth factor
(HGF)) signaling cascade [2], and a set of transcription
factors including hepatocyte nuclear factors 1, 3 and 4
(HNF1, -3 and -4) and CCAAT/enhancer binging protein
group (C/EBP) (reviewed in Ref. [3]). The second group of
studies reported on the proliferative capacity of adult
hepatocytes and the sources of stem cells for hepatic
lineages [4]. The third group of reports has added signifi-
cantly to our understanding of liver regeneration after the
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loss of liver tissue by describing sequential changes and
gene expression in liver. A panel of growth factors including
HGF, epidermal growth factor (EGF), TGF-a and cytokines,
including tumor necrosis factor alpha (TNF-a) and IL-6,
among others, are all tightly involved in the process of liver
regeneration. These ligands recruit a panel of transcription
factors (STAT3, c-fos, c-jun, p53, NFnB, cyclooxygenase-2
(COX-2) and others) to regulate the liver regeneration
process and possibly cell membrane associated proteins
(Fas) [5]. The studies investigating the role of these factors
at the state of liver regeneration utilized various animal
models, as we will describe in this review, to simulate
specific complex clinical conditions of severe or FHF.
In this review we will focus on cytokine signaling path-
ways, primarily the cytokines TNF-a and IL-6, which we
believe are central for future development of new therapeu-
tic reagents and strategies to maintain liver function and
enhance the natural capacity for regeneration of the failing
liver. The review will also describe the clinical condition of
FHF, which is the therapeutic target, and the relevance of
animal models that simulate the clinical FHF state to some
extent.
2. Acute hepatic failure
Acute hepatic failure is a devastating liver disease with a
progressive course. This relatively rare clinical condition
was initially defined by Trey and Davidson [6] in 1970 as a
syndrome of severe hepatitis complicated by the rapid
development of hepatic encephalopathy within 8 weeks of
the onset of jaundice in a patient without a previous history
of liver disease. Later, Bernuau et al. [7] redefined FHF as
the development of hepatic encephalopathy within 2 weeks
of onset of jaundice. Patients who developed encephalop-
athy within 2 to 8 weeks were classified as subfulminant
hepatic failure (SFHF). The etiologies of both conditions are
similar and are listed in Table 1. The underlying causes of
FHF vary in different countries around the world. For
instance, whereas in the western world the current leading
causes for FHF are acetaminophen overdose [8] and other
drug toxicities, in the eastern world hepatitis viruses are the
most common agents (>90%) associated with FHF [9]. In
addition, in the east, hepatitis E virus (HEV) is the most
prevalent single hepatitis virus, while in the west, hepatitis
B virus infection is the leading viral FHF agent [9]. How-
ever, regardless of the etiology, the clinical outcome of all
cases with FHF is very similar, and as such is perceived a
single clinical entity. Despite today’s advanced medical
management, the overall mortality of FHF is very high
(40–80%). The only available proven therapy is liver
transplantation (LTx) [10].
The annual incidence of FHF is estimated to be about
2000 in the US [11]. However, only 10% of those patients
are treated by LTx. Currently the US national registry for
LTx (UNOS) includes 18,210 patients on the waiting list
(August 2001, www.unos.org). Most of these patients will
not be transplanted due to a severe shortage of donor organs.
In 1999, of a total of 4480 patients who underwent LTx in
the USA, only 344 (8.2%) of those were transplanted for
FHF, which amounts to only about 15% of the patients who
were diagnosed with FHF. In addition, the survival rate
following LTx is lower for patients with FHF receiving
cadaveric livers compared to patients with chronic liver
disease. In Europe a total of 3308 patients were transplanted
for FHF during the years 1988 to 2000. The 1-year survival
rate of this group of patients after transplantation is 64%
http://www.eltr.org and [12]), although in recent years in the
US it has been reported to be higher (84%).
The high mortality rate of patients with FHF, together
with the poor availability of liver for transplantation, in
particular in countries with a small population base, and the
relatively low 1-year survival of LTx patients, have moti-
vated innovative research efforts to develop new therapeu-
tics for FHF. A number of experimental drugs are currently
being assessed for their effectiveness in treating FHF. This
includes N-acetylcysteine [13], which was previously pro-
ven as an effective antidote for acetaminophen hepatotox-
icity, and prostaglandins [14]. A number of liver assist
devices have also recently been developed and are now
being tested for their beneficial effect in treating FHF in
Table 1
Etiological agents of acute hepatic failure
Viral Hepatitis viruses A, B ( +D), C, E and G [122]
Spontaneous HBeAg seroconversion,
post chemotherapy HBV reactivation
Hemorrhagic fever viruses, cytomegalovirus,
yellow fever, Q-fever, VZV, TTV, SEN-V family,
herpes simplex viruses, adenovirus
Drugs/toxins
Dose-related Acetaminophen, haloalkalens, carbon tetrachloride,
Amanita poisoning, Bacillus cereus emetic toxin,
cyanobacteria microcystins
Idiosyncratic Isoniazid, halothane, troglitazone, bromfenac,
methyl-dopa, dilantin, valproate, penicillin,
tetracyclines, sulfonamides, quinolones,
allopurinol, PTU, amiodarone, ketoconazole,
NSAIDs, yellow phosphorus, chlorobenzenes,
industrial solvents, herbal medicines
Metabolic/
genetic
Galactosemia, fructose intolerance, tyrosinemia,
neonatal iron storage disease, Wilson’s disease,
alpha-1-antitrypsin deficiency
Neoplastic Metastases: breast, melanoma, lung, lymphoma
Pregnancy-
related
Acute fatty liver of pregnancy, HELLP syndrome
Vascular Budd–Chiari syndrome, veno-occlusive disease,
ischemic shock liver
Miscellaneous Autoimmune hepatitis, primary graft nonfunction
in liver-transplanted patients, heat stroke, sepsis,
liver trauma
Abbreviations: HBV—hepatitis B virus; VZV—varicella-zoster virus;
TTV—transfusion transmitted virus; SEN-V—these are initials of an
infected patient and V for virus; PTU—propylthiouracil; NSAID—
nonsteroidal anti-inflammatory drug; HELLP—hemolysis elevated liver
enzymes and low platelets.
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multicenter trials. These include extracorporeal liver assist
devices containing either human hepatocytes seeded on
hollow fibers [15] or porcine hepatocytes [16]. While the
objective of some of the studies is to sustain the FHF
patient during critical stages as a bridge to LTx, in other
studies the rational has been to sustain the patient until
spontaneous recovery occurs through natural liver regener-
ation. A nonbiological hepatotoxin-removing device, the
molecular adsorbent recycle system (MARS), is also cur-
rently being tested in patients with FHF [17]. Transplanta-
tion of human hepatocytes administered via the portal
system as a therapeutic option to bridge FHF patients had
a low success rate [18]. As is readily apparent from the
current list of novel therapeutic modalities, none, aside from
HGF, is based on the recently delineated role of growth
factors and cytokines in the process of liver regeneration.
HGF, which, as discussed below, functions as a complete
mitogen for hepatocytes [19] and produces an anti-apoptotic
effect [20], has a demonstrated prophylactic effect on
experimental FHF, but has yet to be demonstrated as an
effective therapeutic treatment following the induction of
FHF. This review will suggest some alternative avenues in
this direction based on some of our recent studies. These
new cytokine-based therapeutic strategies may serve as an
alternative to LTx, or additionally as an adjunct to auxiliary,
artificial or xenograft liver assist devices that aim to restore
normal liver function through regeneration of healthy tissue
remnants.
3. Animal models
The current available therapies for FHF are not sufficient
and do not provide an optimal medical solution to most
patients. For the assessment of potential new therapeutic
strategies, an appropriate animal model is important. Vari-
ous pharmacological and genetic FHF animal models have
been developed to support this objective (see Table 2).
However, a major obstacle in developing or choosing a
suitable model is the fact that FHF is a clinical syndrome
induced by a spectrum of etiological agents that, in many
cases, induce liver failure specifically in humans. Hepatitis
viruses that induce FHF in humans do not infect small
animals, and mouse hepatitis virus has no effect on humans.
In addition, the liver is a very unique organ, similar in a way
to the hematopoietic system in that the liver harbors an
integrated regenerative potential. This inherent property
should be taken into consideration when developing animal
models as well as new therapies. As Terbalence and Hick-
man [21] suggested, and we added our modifications, a
number of requirements should be met for a suitable animal
model for FHF: (a) reversibility, and preferentially a dose
dependent model, to enable to assess the model in a
spectrum of doses of the hepatotoxins; (b) reproducible
clinical, biochemical and biological markers as endpoints;
(c) the cause of death should be directly related to the
animal FHF; (d) a therapeutic window resembling the cli-
nical condition of FHF in humans, enabling the assessment
of new drugs; and (e) the toxins and infectious agents
should not induce a health hazard to personnel. Currently
large animal models that meet criteria (a)– (d) are not
available, although animal models for chronic HBV and
HCV infection have been described following the infection
of chimpanzees with these viruses, as well with other human
hepatotropic viruses.
In general, three types of animal models exist: (a)
surgical model; (b) pharmacological; and (c) genetically
modified. These are described below with reference to the
role of cytokines in the etiology of the pathological
condition.
3.1. Surgical models
Since the early days of modern hepatology numerous
surgical models have been developed and heavily utilized in
liver regeneration studies. However, in most cases, these
models are not relevant to the human clinical FHF syndrome
induced by nonsurgical or traumatic events normally seen in
the clinic (for review of these models see Ref. [22]).
Table 2
Pharmacological and genetic models of acute hepatic failure
Model Treatments Animal
D-Galactosamine glycine and uridine [29],
alanine [30], HGF [31],
hyper IL-6 [103]
mice [23],
rats [24],
rabbits [25],
dogs [26]
Acetaminophen
(paracetamol)
anti-Fas antisense
(ISIS 22023) [48],
dogs [123],
pigs [124]
Carbon tetrachloride rats [125],
mice [126]
Thioacetamide DMSO and DMTU [127],
hypothyroidism [34]
rats [128],
mice
Concanavalin A phosphodiesterase
inhibitors [129]
pentoxifylline [36]
mice [130],
rats
LMW-HA [44],
NC-1500 [131],
anti-IL-12 Ab [132],
caspase inhibitors [133]
rats, mice
cell transplantation [134],
non-peptide RGD
analog [135],
hypothyroidism [136]
Fas-mediated interleukin E [137],
IL-15, anti-Fas antisense
(ISIS 22023) [48]
mice
[138,139]
IL-4 caspase inhibitors [40] mice [40],
rats [140]
Lipopolysaccharide KGF [141],
etoposide [142]
rats [143],
mice
Genetically modified:
Alb-uPA (nu/nu) hepatocyte transplantation mice [52]
FahDexon5 hepatocyte transplantation mice [53]
IL-6 / IL-6 mice [80]
iNOS-null mice [144]
DT-A mice [56]
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3.2. Pharmacological models
A number of hepatotoxins have been used to induce FHF,
and most investigators apply one of these agents from this
group, although the exact mechanism of FHF development
following the administration of some of these toxins is not
clear. It is also important to keep in mind that different
animal species will respond differently to a particular
hepatotoxin. This can be due to basic metabolic differences
between species of animals, as well as differing genetic
backgrounds between strains of the same species, or even
within a given strain originating from different animal
farms. In addition, differences in environmental conditions
can also be important. In this group of animal models the
following reagents were used: D-galactosamine (D-gal),
acetaminophen (APAP), carbon tetrachloride (CCl4), thio-
acetamide (TAA), concanavalin A (Con A), lipopolysac-
charide (LPS) and anti-Fas antibodies (i.e. Fas activation).
3.2.1. D-Gal
This hepatotoxin has been used extensively in a number
of FHF animal models including mice [23], rats [24], rabbits
[25] and dogs [26]. D-Gal is an intracellular uridine depleter,
which blocks transcription. Reduced protein synthesis
results in hepatocytes apoptosis followed by necrosis [27].
In addition, D-gal probably also enhances intestinal endo-
toxines, and TNF-a is suggested to mediate some of the
apoptotic effect on hepatocytes [28]. This model has been
applied to assess the role of a number of reagents in
preventing FHF [29–31].
3.2.2. Acetaminophen
This drug is becoming the leading cause of FHF in
humans in the western world. Acetaminophen is metabo-
lized by the P450 cytochrome oxidase system in the liver
and results in the production of hepatotoxic metabolite, N-
acetyl-p-benzoquinoneimine (NAPQI). Excess consump-
tion/administration of acetaminophen results in the produc-
tion of intolerably high levels of NAPQI that induce
hepatocyte specific cell damage through the production of
free oxygen radicals, nitrites and nitrates [32].
3.2.3. CCl4
CCl4 has been used extensively to induce liver damage in
animal models. CCl4 induces FHF as well as liver cirrhosis,
depending on the route of administration and dose. CCl4 is
metabolized by cytochrome P450 2E1 in the liver to produce
a toxic metabolite. CCl4 hepatotoxicity has been demonstra-
ted to induce liver necrosis as well as apoptosis [33].
3.2.4. TAA
TAA is metabolized through the flavine adenine dinu-
cleotide monooxygenase system to form TAA-S-oxide.
Low-dose TAA will induce apoptosis and higher doses will
cause also liver necrosis [34]. TAA was used in the rat FHF
model to assess various reagents [35].
3.2.5. Con A
Con A is a plant lectin used extensively to induce liver
damage in various mice strains [36,37], sparing other
organs. Con A has a toxic effect on hepatocytes, however,
this is an indirect effect mediated through CD4 cell
activation and release of cytokines (TNF-a, IL-10, IL-4
and interferon-g). In addition, in this model an up-regu-
lation of ICAM-1 and VCAM-1 was also documented,
which might play a role in intrasinusoidal hemostasis [38]
and represent a defense mechanism [39]. TNF-a and IL-4
are the inducers of hepatocyte apoptosis, and IL-10 pro-
duces a protective effect [40]. Furthermore, both TNF-R1
and TNF-R2 knockout mice are resistant to Con-A-induced
apoptotic liver injury [41], indicating both the essential
role of TNF-a and the cooperative relationship between
the receptors in the development of FHF in this model.
Interestingly the TNF-a effect depends on the liver tran-
scriptional state. Only in a state of transcriptional arrest
will Con A induce caspase-3-dependent liver damage [42].
In a nontranscriptional arrest state, TNF-a induced liver
damage is independent of caspase-3. This finding was
supported by the report that Con A liver damage is
dependent on caspase-1 [43]. From applying the Con A
model it is also apparent that liver NK 1.1+ cells are key
players [44]. Pretreatment with low-molecular-weight hya-
luronic acid which depleted the liver of NK 1.1+ cells
probably suppressed the TNF-a apoptotic effect inducing
liver damage, through prevention of caspase-3 activation.
Neutralizing the NF-nB signaling could inhibit this hep-
atoprotective effect. On the other hand, other investigators
had reported that CD44 knockout mice are more suscep-
tible to Con A-induced hepatitis [45]. It was suggested that
Fas ligand expression on NKT cells plays a pathogenetic
role [46]. The role of Fas is not clear in this model,
although liver damage was suggested to be mediated
through Fas ligand [47], and mice were protected from
Con A-induced liver damage by Fas antisense [48]. The
Con A-mediated immune liver injury of mice was also
assessed in inducible nitric oxide (iNOS) knockout mice
[49]. These mice were protected from Con A-induced liver
damage, although susceptible to TNF-a administration,
suggesting that the iNOS effect is upstream of TNF-a,
probably enhancing TNF-a production mediated by NO.
3.2.6. LPS
LPS is a gram-negative cell wall component. High
concentration of LPS mediates Kupffer cell activation
and liver damage [50]. Kupffer cell activation induces
neutrophil adherence to sinusoidal endothelial wall, release
of reactive oxygen species (ROS), cell injury, platelet
aggregation and further tissue injury [51]. Various models
have been described in which LPS is used in combination
with other hepatotoxins including D-gal, halothane, CCl4
and alcohol [22,51]. These models are not applicable to
FHF studies due to differences in the time frame of disease
development.
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3.3. Genetically modified animals
The first directed genetically modified animal developed
specifically to study FHF, liver regeneration and transplan-
tation was the alb-uPA transgenic mouse [52]. In this nude
(nu/nu) mice strain, the albumin promoter is driving the
urokinase-type plasminogen (uPA) activator. The ectopic
uPA overexpression in the mice is lethal to hepatocytes
and animals die of FHF early on, unless the alb-uPA trans-
gene is inactivated via a spontaneous mutation during
development. Using a gene knockout approach which
targeted the fumarylacetoacetate hydrolase (FAH) gene,
resulting in the FahDexon5 mice (FAH /), Overturf et al.
[53] generated a genetic model for hereditary tyrosinemia
type I. In the hepatocytes of these mice, hepatotoxins
accumulate causing FHF. Both the FAH / and the alb-
uPA animal models, as well as additional models [54,55],
have served mainly for studying metabolic disease patho-
physiology, hepatocellular growth and the potential of
hepatocyte transplantation and proliferative capacity (which
is discussed below). Recently a very elegant and potentially
useful diphtheria toxin (DT) receptor-mediated conditional
transgenic mice animal model was developed [56]. Murine
cells have no natural DT receptor (DT-R), and consequently
mice are resistant to DT administration. Expression of the
human DT-R in transgenic mice by using the albumin
promoter sensitized the hepatocytes and the mice to injected
DT, causing liver damage and FHF. The significant advant-
age of this model is that the dose of DT determines the
extent of cell death and hepatotoxicity.
There are a number of available animal models for FHF.
However, it is of utmost importance to tailor the relevant
model to the objective of the study. In some cases where the
objective is to assess the role of factors, such as p27Kip1
[57], in hepatocyte proliferation, a genetically modified
model, e.g. FahDexon5, would be appropriate. However, in
most cases, murine and rat FHF models do not simulate the
FHF condition of humans well. The reproducibility of FHF
induction by a specific reagent is relatively poor in most
pharmacological models. Moreover, there is no available
small animal model to simulate human condition of FHF
induced by hepatitis viruses, and human hepatitis viruses do
not induce FHF in chimpanzees. Thus, it is difficult to
extrapolate the therapeutic effects of various cytokines and
other reagents from studies in small animal models to the
pathophysiology of human FHF, where the results could be
significantly different. Nevertheless, small animal models
provide a useful paradigm for testing the basic concepts of
novel therapeutic strategies that can be further tested in
clinical trials.
4. Hepatocyte proliferative capacity and stem cells
Following major tissue loss, the liver has a remarkable
and apparently almost unlimited capacity to regenerate. This
has been demonstrated in recent studies utilizing a number
of experimental models. The widely utilized model of liver
growth following partial hepatectomy (PHx), first described
in 1931 by Higgins and Anderson [58], involves the surgical
removal of specific lobes amounting to approximately two-
thirds of the liver mass. The residual, undamaged lobes
enlarge to compensate for the deficiency in hepatic mass,
although the resected lobes never grow back. Following
PHx, hepatocytes divide once or twice in a process lasting
24 to 48 h, and the rest of the liver lineages follow during
the next 5 days and return to quiescence. This process can
be repeated, and the rat liver is able to regenerate each time
and achieve its previous mass, even following up to 12
sequential resections [59]. Regeneration following hepatec-
tomy involves the proliferation of all the existing mature
cellular populations composing the liver (for review see Ref.
[60]). Experimental animal model studies based on serial
transplantation and liver repopulation following damage
have further demonstrated the almost unlimited replication
capacity of adult hepatocytes. Sandgren et al. [61] observed
that in the alb-uPA transgenic mice, which, as mentioned
above, experience severe liver damage and postnatal death
of most pups, repopulation of nearly the entire liver occurs
through proliferation of spontaneously generated transgene-
deficient progenitor cells that represented approximately 1%
of the hepatocyte population. Subsequent studies by Rhim et
al. [52,62] showed that transplantation of both syngeneic
and xynogeneic (rat and human) adult hepatocytes could be
utilized to reconstitute the damaged livers of the newborn
alb-uPA mice. Transplanted liver cells repopulated nearly
the entire diseased recipient liver requiring an estimated 12-
18 rounds of cell division. Using a gene knockout approach,
Overturf et al. [63] created a mouse model of liver repopu-
lation based on the human disease hereditary tyrosinemia
type I, which is due to a lack of the enzyme FAH, and
renders a selective advantage to transplanted wild-type
hepatocytes. In similar hepatocyte transplantation-repopula-
tion studies using the FAH / mouse model described
above, Overturf et al. [63] found that normal male adult
hepatocytes, when transplanted to female FAH knockout
recipients, could repopulate the recipient animals liver to
>90% within 6 to 8 weeks. Rescue of FAH-deficient
animals and restoration of liver function required as few
as 1000 donor cells [53]. Furthermore, the genetically
marked donor hepatocytes could be reisolated from repopu-
lated recipient liver and retransplanted in limiting numbers.
This process could be successfully repeated in a serial
fashion at least eight times with no apparent decrease in
proliferative potential and with no evidence of abnormal
liver function or hepatic architecture. This experiment
demonstrated that the regenerative potential of hepatocytes
exceeds 69 cell doublings, equivalent to a 7.3 1020-fold
expansion, and is similar to that of hematopoietic stem cells.
Further analysis of the repopulating cells in this system has
revealed that hepatocytes are not all alike [64]. The larger,
binucleated hepatocytes appear to have a larger repopulating
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capacity than the smaller, mononucleated cells. However,
the number of previous cell divisions, e.g. the ‘‘age’’ of the
hepatocytes, neither increased nor decreased the repopula-
tion capacity. By tagging the hepatocytes using a retroviral
vector, it was established that the liver-repopulating cells
occur at a frequency of >1:10,000. Moreover, the observa-
tion by these investigators that a polyclonal population of
repopulating cells could become monoclonal on subsequent
rounds of serial transplantation indicates that the majority of
adult mouse hepatocytes have the ability to produce one
round of liver repopulation. Thus, an important conclusion
from this study is that short-term therapeutic liver regener-
ation does not appear to require a progenitor or stem cell
[64]. Nevertheless, it is of great interest that in the adult
animal a number of cell types, both hepatic and nonhepatic,
retain the ability to differentiate into hepatocytes. Further
understanding of these mechanisms governing this phenom-
enon could enhance the development of novel therapies for
tissue regeneration, and not solely for hepatocytes.
For more than a decade it has been known that epithelial
cells that line the bile ductules (Canals of Herring) in adult
animals and humans have the capacity to differentiate into
hepatocytes and biliary ductule cells (reviewed in Ref. [65]).
Following toxic injury or massive necrosis, there is prolif-
eration of an ‘‘oval cell compartment’’ originating from the
ductular cells. Oval cells are heterogeneous with differing
precursor capabilities and appear to form a reservoir capable
of forming both mature hepatocytes and bile duct cells after
toxic injury or massive necrosis. Proliferation of oval cells is
readily apparent following the induction of liver damage in
experimental animal models, and these cells participate in
the process of liver repopulation in humans following acute
massive necrosis and chronic liver disease.
Recently, it has become evident that bone marrow-
derived cells also appear to provide a reservoir of hepato-
cytes and oval cells. This phenomenon was first hinted at by
the unexpected observation that adult oval cells in the liver
express the Thy-1 cell surface marker, which is most
commonly used in conjunction with CD34 and other
markers to identify hematopoietic cell populations [66].
Subsequently, using a combination of 2-acetylaminofluor-
ene to block hepatocyte proliferation, and hepatic injury to
induce oval cell proliferation in bone marrow or whole liver
transplanted rats, Petersen et al. [4] observed the appearance
of oval cells bearing the genetic marker (Y chromosome) of
the transplanted bone marrow cells. In a study of similar
design Theise et al. [67] observed that in recipient mice of
cross-sex bone marrow transplantations, up to 2.2% of the
hepatocytes bore the Y chromosome of the FACS sorted
CD34+Lin donor bone marrow cells. The high levels of
hepatocytes of donor origin observed in this later study may
have been due to the use of agents that inhibit hepatocyte
proliferation following treatment of the mice with high-level
irradiation, which is known to induce liver damage and
regeneration [68]. In separate studies, using bone marrow-
derived cells from wild-type FAH mice transgenic for the
Escherichia coli lacZ gene, Lagasse et al. [69] again applied
the FAH / liver repopulation mouse model to show that
only a specific bone marrow-derived subpopulation of the
cells, the hematopoietic stem cells (HSCs), which are
characterized by the cell surface markers as c-kithigh
ThylowLinSca-E+ by fluorescence-activated cell sorting,
were capable of liver repopulation.
Thus, even though most adult mouse hepatocytes posses
the potential to produce one round of liver repopulation, and
short-term liver regeneration would not appear to require a
stem cell [64], it is apparent that, given the opportunity,
HSCs are capable of making significant contributions
towards liver regeneration following hepatic failure.
Although the actual extent of the participation of HSCs in
liver regeneration is not known, anecdotal evidence derived
from analysis of human patients transplanted with bone
marrow cells or whole liver transplants would suggest that
the contribution of bone marrow derived stem cells to liver
repopulation can be substantial [70,71]. Taken together,
these observations indicate that both small animals and
humans are endowed with redundant systems and an abun-
dance of cellular resources that can be readily conscripted to
regenerate normal functional tissue even following cata-
strophic loss of liver parenchyma. The recent findings of
trans-differentiation of hematopoietic and pancreatic cells
into hepatocytes suggest that this process could also be
activated in vivo. Major molecular effectors in this process
could be cytokines and growth factors.
5. Cytokines in liver failure and regeneration
Regeneration of liver parenchyma following mechan-
ical, chemical or immune related injury is a tightly
controlled and molecularly complex process extending in
time from days to weeks or months. Studies of liver
regeneration, spanning nearly a century, and involving the
morphological, physiological, biochemical and molecular
aspects of liver regeneration have helped to delineate the
events that trigger liver regeneration. Several recent
reviews, to which the reader is referred [60,65,72], have
discussed in detail the molecular mechanisms involved in
liver regeneration. Here we shall highlight the roles of
two cytokines, TNF-a and IL-6, and present brief com-
ments regarding these events.
A precipitous deficit in metabolic capacity, for instance
resulting from the loss of tissue mass experienced follow-
ing PHx, produces an immediate cellular and molecular
response entailing the release of cytokines TNF-a and IL-
6, and growth factors, of which HGF and also TGF-a and
EGF appear to be most important. A general picture has
emerged suggesting that regeneration occurs through a
multi-step process involving at least two distinct steps: a
‘‘priming’’ phase involving the transition of quiescent
hepatocytes from the G0 into the G1 phase of the cell
cycle, and the progression of the cells past the restriction
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point within G1 [65]. Studies utilizing the PHx liver
regeneration model, together with genetically modified
mice strains, have demonstrated that cytokines are central
mediators in both phases of this process, priming by TNF-
a and IL-6, and progression by growth factors HGF, TGF-
a and EGF. Signal transduction pathways activated by
cytokine signaling, as well as the increase in other factors,
such as ROS, set in motion a cascade of molecular events
including the translation-independent activation of tran-
scription factors, such as NFnB, and global changes in
gene expression. In the initial phase of regeneration,
changes in gene expression include the induction of imme-
diate early genes, such as proto-oncogenes c-fos, c-jun, and
c-myc, which ultimately stimulate the normally quiescent
hepatocytes to enter the cell cycle. These events are
depicted schematically in Fig. 1.
The orchestrated events occurring following the expo-
sure of the liver to FHF inducers suggest that it is a very
complex affair. Furthermore, the nutritional state, the
presence of hepatic steatosis or steatohepatitis [73], or
EtOH exposure [74], and most probably the genetic back-
ground of the individual (e.g. cytochrome P450 polymor-
phisms), or animal strain (e.g. BALB/c vs. C57BL/6), can
determine the ultimate response to cytokine signaling and
influence the outcome of the FHF condition. Prior to the
effect that TGFa and EGF could induce, a panel of
cytokines, in conjugation with the HGF [60], mainly IL-
6 and TNF-a, prime hepatocytes to regeneration. Two
intracellular signaling mediators, STAT3 and NFnB, are
activated immediately following PHx. The level of expres-
sion of these two key players will determine the faith of
the damaged liver; see Fig. 1. Both of these mediators are
downstream signaling mediators of IL-6 and TNF-a,
respectively. Similarly, the transcription factors AP1 and
LRF1 are both increased after PHx; both participate in
intracellular signaling leading to DNA synthesis. The
activation of most of these proteins does not require
protein synthesis, but rather are dependent on posttransla-
tional mechanisms. Interestingly, under ‘‘normal physio-
logical’’ conditions, the healthy liver produces undetectable
to very low levels of cytokines including IL-4, IL-6, IL-10,
IL-12, IL-13 and IL-15, and very low levels of TNF-a,
LTh, IL-1a, IL-1h and IL-18 (reviewed in Ref. [72]). The
most prominent known cytokine player in liver injury and
regeneration is TNF-a. In addition to the elevation of
TNF-a expression following liver injury, TNFR1 and
TNFR2 expression both increased in acute and chronic
liver disease [39]. Paradoxically, TNF-a, which exerts its
activity through TNFR1 and TNFR2, is involved in death
signaling as well as in liver regeneration cascade. One of
the prominent products of TNF-a signaling is IL-6. Both
TNF-a and IL-6 and their ‘‘derivatives and relatives’’, i.e.
antagonists and agonists/superagonists, encounter therapeu-
tic potential. An additional cytokine IL-1 also plays a role
in liver regeneration through activation and translocation
of NFnB [75].
5.1. TNF-a signaling and effects during liver regeneration
TNF-a mediates multiple signaling transduction path-
ways in hepatocytes. The results of these signaling events
could cause either hepatocyte death or proliferation. TNF-a
signaling is mediated through two cell surface receptors,
TNFR1 and TNFR2. TNF-a signaling could in some con-
ditions, such as in combination with D-gal administration
[76], enhance the apoptotic pathway by activating the
TNFR1 downstream cascade recruiting TRADD, caspase
8 and the down stream caspase 3 proteases, resulting in
apoptosis. These events are conjugated with the D-gal
effects, which induce apoptosis through suppression of
protein production. However, in case TNF-a is administered
alone or prior to the administration of D-gal, the survival
signal of TNF-a prevails. Altogether, these findings as well
as others (for review, see Refs. [65,72]) suggest that the key
factor that determines the effect of TNF-a at the state of
liver regeneration is the activation and nuclear translocation
of NFnB [77]. Following PHx, NFnB activation occurs
rapidly within 30 min. This occurs through the production
of ROS, apparent as early as 5 min after PHx. The
production of ROS leads to InB phosphorylation, ubiquiti-
nation and degradation, thus enabling NFnB nuclear trans-
location and downstream gene activation, including IL-6
and ICAM-1.
One important factor activated following PHx is JNK
kinase. The expression of JNK is at least partially dependent
on TNF-a. JNK phosphorylates c-jun, an essential factor in
liver development and regeneration. In addition, JNK is
required for EGF function in the state of liver regeneration.
TNF-a also induces the expression of pro- and anti-apoptotic
intracellular protein members of the bcl-2 family, including
bak, bax and bad (pro-apoptotic) as well as bcl-2, bfl-1 and
bcl-xl (anti-apoptotic). The net effect of TNF-a on the bcl-2
family members is probably in favor of the anti-apoptotic
effect [72]. One cytokine, which encounters a feedback effect
on TNF-a, is IL-10 that down-regulates TNF-a expression.
The effect of TNF-a on liver regeneration is probably
dependent on the timing and doses of exposure to environ-
mental factors (e.g. nutritional) as well as the genetic back-
ground, which determine the overall result.
A very recent report on the possible role of COX-2 in
liver regeneration could explain the devastating contribu-
tion which nonsteroidal anti-inflammatory drugs (NSAIDs)
make to the development of liver failure [78,79]. A group
of patients with Reye’s syndrome (defined as an acute
systemic disease of the young with progressive central
nervous system damage and liver failure) was associated
with Aspirin consumption. Prostaglandin E2 (PGE2) con-
tributes significantly to the regenerating liver. PGE2 is
produced by COX-2, which is highly expressed in the
regenerating liver. The transcription factor C/EBPa expres-
sion is suppressed after PHx, coincides with increased
COX-2 expression, and concomitantly with increased
expression of C/EBPh and C/EBPy [78,79], both of which
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release the cell from the p21/WAF G1 block, and promote
the expression of cell cycle progression proteins cyclin D2,
cyclin A and retinoblastoma protein. Aspirin, a member of
the NSAID family, is a nonselective COX inhibitor. Con-
sumption of this drug could contribute to suppression of
liver regeneration at a state of liver damage. Overall this
reinforces the recommendation to avoid NSAID use at the
stage of liver damage, enabling the cytokines and growth
factors to execute their liver regenerative effect.
5.2. The role of IL-6 in liver regeneration
Recent reports have unequivocally determined that IL-6
is a key factor in liver regeneration. The most significant
Fig. 1. This cartoon summarizes some of the events that follow acute liver damage, such as partial hepatectomy or exposure to hepatotoxins, as described in
Section 3 of this review. Shortly after liver injury, numerous molecular signaling pathways are activated and some are suppressed. For each and every
hepatocyte the survival and death signals are coactivated. In cases in which STAT3 and NFnB are dominant and their effector molecules are not suppressed, the
survival signal will prevail. In those instances in which the apoptotic effector molecules are highly expressed, cells are in greater danger to die. New
therapeutics for acute liver failure should balance the cell to increase the anti-apoptotic signal and enhance the cell into cell cycle. Hyper-IL-6 could serve as a
potential candidate that meets these criteria, as shown in this illustration. The abbreviations in this figure are explained in the text. (This drawing was made by
Ms. Reuth Galun.)
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contribution to this concept was the report from Taub’s
group that IL-6 knockout mice suffer from impaired liver
regeneration, which could be reversed by IL-6 [80]. Fur-
thermore, the impaired liver regeneration in TNFR1 knock-
out mice could also be reversed by IL-6. The effect of IL-6
is mediated through STAT3, which is phosphorylated and
translocated into the nucleus. The phosphorylated STAT3
dimer induces the expression of a panel of genes involved in
inflammation, acute phase response and cell cycle progres-
sion from G1 to S phase. IL-6 signaling initiates following
the binding of IL-6 to gp80 (IL-6Ra) and then interacts with
gp130 (IL-6Rh) as described in other chapters of this
volume. STAT3 activation in collaboration with additional
transcriptional factors C/EBPh and AP1 enhances the
expression of additional factors, such as NF-IL-6, c-myc,
c-fos, IRF-1 and others, enabling cells to progress into cell
proliferation. However, timing may be an important factor
in determining the outcome of gp130 stimulation with
respect to liver injury and regeneration. Wustefeld et al.
[81] have observed that gp130 hyper-stimulation by IL-6
administration to sIL-6R transgenic mice 3 h prior to
hepatectomy resulted in a delay and inhibition of hepatocyte
proliferation. The apparent contradiction in these observa-
tions may be explained by the 40-fold induction of sup-
pressors of cytokine signaling (SOCS) that occurs within 2 h
following IL-6 administration [82]. SOCS, in particular
SOC-3, appear to participate in a negative-feedback loop
that turns off IL-6-mediated STAT3 signaling and is thought
to ensure termination of the priming phase of liver regen-
eration [82]. Thus, IL-6-mediated induction of SOCS prior
to the induction of liver injury may inhibit gp130 stimula-
tion-enhanced liver regeneration observed following hepa-
tectomy.
The activation of the IL-6/STAT3 signaling is not only
important following PHx but also essential in recovery from
cold ischemia and reperfusion prior to LTx [83]. Further-
more, one of the most striking observations of livers under-
going regeneration after PHx is the stringent control of
metabolic homeostasis. One example is the maintenance of
glucose balance following the loss of massive liver tissue by
up-regulating the expression of genes involved in gluconeo-
genesis [84]. STAT3 as well as AP1 and HNF1 interact
adaptively to liver injury by amplifying hepatic genes to
maintain metabolic homeostasis [85].
6. Cytokine signaling promotes protective anti-apoptotic
functions
A curious relationship, it has recently been noted, exists
between liver injury and repair, whereby induction of a
moderate level of injury confers resistance to a subsequent
larger and otherwise lethal insult to the liver. Protection
following ischemic injury, also called ischemic precondi-
tioning, is one example of this phenomenon. While initially
reported in myocardium following ischemia-induced injury
[86], ischemic preconditioning-induced protection has since
been observed in other tissues, including the liver [87].
Ischemia–reperfusion-based liver injury is largely apopto-
sis-driven [88]. However, a 10-min period of ischemic
preconditioning, followed by 15 min of reperfusion signifi-
cantly reduced the number of TUNEL positive hepatocytes
and sinusoidal endothelial cells, and increased survival in
mice subjected to sustained insult ranging from 75 to 90 min
of ischemia [87].
Other forms of liver injury can also induce a protective
state. The onset of liver regeneration following PHx delays
or prevents hepatocyte apoptosis in response to Fas engage-
ment, and can protect mice against the lethal effects of a Fas
agonist at certain doses [89,90]. The level of Fas expression
on the cell surface of hepatocytes following PHx is not
down-regulated. Thus, the protective effect of PHx cannot
be attributed to a trivial explanation, such as a lack of
available Fas. Rather, a mechanism of injury-induced pro-
tection appears to directly inhibit the activation of molecular
pathways responsible for cellular self-destruction. In ani-
mals that received either PHx or ischemic preconditioning
prior to sustaining an otherwise lethal insult, the activity of
caspase-3, also known as the ‘‘executioner’’ because of its
direct role in programmed cell death, was dramatically
diminished [87,89]. PHx prior to Fas activation also pre-
vented the decrease in FLIPL, the long form of FLICE
(caspase 8) inhibitory protein, which is reduced 500% in
mice following treatment with Fas-specific antibodies alone
[90]. This observation correlates well with the earlier
observations of Tzung et al. [91] who noted significant
changes in the expression of a number of apoptosis-related
genes during the early phase following PHx-induced regen-
eration. These changes in gene expression included an early
decline in the mRNA levels of three pro-apoptotic genes,
Bax, Bad and Bak, and an increase in Bcl-x mRNA, with a
corresponding increase in hepatocyte localized Bcl-xL pro-
tein that reached peak levels 12 h post PHx (mid-G1 phase
of the cell cycle). Thus, the protective affect that is observed
following liver injury and regeneration can be directly
attributed to changes in the expression of factors that
participate in the activation or inhibition of the apoptotic
cell death program in the liver.
From this apparently tight linkage between liver regen-
eration and the injury-induced pro-survival effect, it is not
surprising that a clear molecular relationship has emerged
whereby the signaling factors that mediate liver regeneration
also affect anti-apoptotic factors. TNF-a, which is re-
quired for liver regeneration, also appears to play an
important role in the PHx-induced anti-apoptosis protec-
tive state. This is surprising because, as noted above,
TNF-a is a pro-inflammatory cytokine and a mediator of
the acute phase response that induces apoptosis in a
variety of cell types, including hepatocytes, when admin-
istered to mice sensitized by treatment with transcrip-
tional inhibitors, such as D-gal [92,93]. TNF-a-induced
cell death is mediated through one of its two receptors,
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TNFR1, which shares homology with Fas in its C-
terminal intracellular domain referred to as the ‘‘death
domain’’. Both Fas and TNFR1 use similar types of
associated molecules in the signal transduction pathway
leading to apoptosis [94]. Nevertheless, Takehara et al.
[89] observed that inhibition of TNF-a by prior admin-
istration of anti-bodies to TNF-a abolished the limited
PHx-induced protective effect against Fas-mediated hep-
atocyte apoptosis. Furthermore, pretreatment of mice with
TNF-a prior to Fas-activated apoptosis decreased cas-
pase-3 activity and prolonged animal survival, similar to
PHx pretreatment. Nagaki et al. [76] observed that TNF-
a pretreatment prevented TNF-a-induced apoptosis and
prevented FHF in D-gal-sensitized mice, also through a
mechanism involving inhibition of caspase-3 activity.
Surprisingly though, TNF-a pretreatment did not provide
a protective effect against Fas-mediated apoptosis that
was observed by Takehara et al. [89]. However, this
observation may have been due to the choice of the
more stringent end-point of ‘‘total survival’’ rather than
‘‘prolonged survival’’ used by Takehara et al. [89].
The TNF-a signal transduction pathway in liver regen-
eration following PHx- or CCl4-induced liver injury fol-
lows the sequence TNF-a!TNFR1!NFnB! IL-6!
gp130! STAT3 [65]. Induction of protection against apop-
tosis-mediated liver failure also seems to involve similar
molecular components. Blockage of NFnB function either
by expression of a dominant InB mutant (DN-InB) [95,96]
or by treatment with NFnB inhibitors, such as the fungal
metabolite gliotoxin [77], has demonstrated that NFnB is
important in directing the TNFR1 signaling towards cell
cycle progression and preventing apoptosis both in vitro
and in vivo. Similarly, Nagaki et al. [76] observed that
expression of an adenoviral-encoded dominant InB mutant
abolished the protective effect of TNF-a pretreatment in
preventing TNF-a/D-gal-induced apoptosis. NFnB is
required for induction of nitric oxide synthetase (iNOS)
and NO production in both TNF-a- and Fas agonist-treated
hepatocytes, and NO protects hepatocytes from both TNF-
a- and Fas-mediated apoptosis in vitro [97]. NO has also
been shown to be a mediator of ischemic preconditioning
[98]. Moreover, NFnB also directly regulates the expres-
sion of distinct pro-survival factors in the Bcl-2 family,
such as Bcl-xL and Bfl-1/A1 [99]. Thus, NFnB appears to
directly participate in mediating the anti-apoptotic by
effecting gene expression.
IL-6, which is a known anti-apoptotic factor, has been
shown to render protection in animal models of FHF that
were only later shown to be mediated through mechanisms
involving hepatocyte apoptosis. Thus, pretreatment with IL-
6 protected both normal rats and IL-6-deficient mice from
warm ischemia/reperfusion injury [100]. IL-6 pretreatment
also protected mice from endotoxin shock induced by either
Staphylococcus aureus endotoxin B following D-gal sensi-
tization [101], or by challenge with a lethal dose of LPS
[102]. Recently, we have reported a direct anti-apoptotic
effect of gp130 hyper-stimulation in rats administered with a
lethal dose of D-gal [103]. Hyper-IL-6 is a super agonistic
protein consisting of IL-6 covalently linked to the sIL-6R by
a short, flexible polypeptide linker [104]. Hyer-IL-6 is fully
active on gp130 expressing cells and is significantly more
potent than unlinked IL-6 and IL-6R both in vitro and in
vivo. The super-agonistic activity may be due in part to both
its higher affinity to gp130 and the longer lasting activity of
this protein on cells, and to its longer in vivo half-life [105].
Administration of hyper-IL-6 to D-gal-treated rats reduced
the number of TUNEL positive hepatocyte nuclei more than
fourfold in comparison to treatment with IL-6 [103].
These observations indicated the importance of IL-6 as a
pro-survival factor of apoptosis-mediated liver injury. How-
ever, only recently has a direct mechanistic role for IL-6 as
a critical anti-apoptotic factor begun to be elucidated. IL-6
induces anti-apoptotic effects in hepatoma cells by sup-
pressing the TGF-h-induced caspase -3 expression via a PI
3-kinase/Akt- and the STAT3-dependent pathway [106].
Kovalovich et al. [107] observed that IL-6 / mice are
significantly more sensitive than IL-6+/ + mice to apoptotic
liver injury induced by the Fas agonist, Jo-2 mAb. How-
ever, pretreatment of both wild-type and IL-6 / mice
with recombinant IL-6 significantly reduced the level of
Fas agonist-induced apoptosis and increased survival rates
compared to untreated controls. The mechanism of the IL-
6-induced anti-apoptotic effect could be related directly to
the expression levels of specific pro-survival factors in the
liver. Thus, as observed by Kovalovich et al. [107], in IL-
6 / mice the constitutive levels of Bcl-2 and Bcl-xL are
reduced 7.4- and 3.0-fold, respectively, in comparison to
wild-type mice, and remain anomalously low following Fas
agonist-induced injury. Similarly, expression of FLIP,
which strongly inhibits caspase 8 (FLICE), is constitutively
expressed at 1.4-fold lower levels in the absence of
endogenous IL-6 [107]. Moreover, whereas FLIP levels
drop rapidly in IL-6 / livers following Jo-2 treatment, in
IL-6+/ + livers they remain stable for 12 h [107]. This
instability of FLIP could be corrected in the IL-6 / mice
by pretreatment with IL-6. Because IL-6 did not induce
FLIP expression above basal levels, it was suggested that
IL-6 functions by maintaining existing FLIP protein levels
[107]. The end-result of the respective low levels or rapid
disappearance of the pro-survival factors is an accelerated
activation of procaspases -8 and -3 following Fas agonist
treatment. Taken together, these observations suggest that
IL-6 functions as a critical mediator of pro-survival factors
in the liver.
Treatment of primary hepatocytes in vitro with HGF or
administration of HGF to mice prior to induction of Fas
agonist (Jo-2 mAb)-mediated hepatocyte injury has also
been observed to prevent Fas-mediated hepatocyte apopto-
sis and FHF [108]. HGF pretreatment increased levels of
Bcl-xL protein but not Bcl-2 in the liver and prevented the
activation of caspase-3. The molecular signal transduction
mechanism by which HGF affects the apoptotic apparatus is
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currently not totally clear. However, it has been observed
that BAG-1, a Bcl-2-binding anti-apoptotic protein [109],
binds to the intracellular domain of the c-MET/HGF recep-
tor, and overexpression of BAG-1 in liver progenitor cells
enhances protection from apoptosis [20]. Altogether, these
observations suggest that cytokine signaling orchestrates a
direct and concerted mechanism connecting the molecular
functions regulating liver regeneration together with the
activation of pro-survival factors that play a substantial role
in protecting the liver against further injury.
7. Therapeutic cytokine intervention in liver failure
The notion that the measured and timely administration
of cytokines can serve as a therapeutic strategy for the
treatment of hepatic failure has been explored in a number
of animal models in recent years. Underlying this notion is
the basic premise that liver regeneration can indeed be
accelerated which is supported by the observation that liver
regeneration following PHx in transgenic mice overexpress-
ing HGF is completed in half the time compared to normal
mice [110]. However, not only complete mitogens, such as
HGF, can accelerate regeneration. Peters et al. [111] have
shown that activation of gp130 intracellular signaling using
the IL-6/sIL-6R fusion protein, hyper-IL-6, 2 h following
50% PHx in mice induced the complete recovery of liver
mass after as little as 48 h, as compared to 5 to 6 days in
untreated, or IL-6-treated subjects. This differential effect of
hyper-IL-6 compared to IL-6 may be attributed in part to
the longer half-life of the fusion protein in vivo, as well as
to the higher affinity of hyper-IL-6 to gp130, the compa-
ratively less efficient internalization of the hyper-IL-6/
gp130 receptor complex, and longer-lasting activity on
cells [105].
Unlike the precipitous loss of hepatic mass represented in
the model of regeneration following PHx, acute and fulmi-
nant hepatic failure is most commonly the end-result of a
complex and progressive process, often involving apoptosis
and necrosis of hepatic parenchyma associated with an
immune mediated inflammatory response. The ability of
cytokines to enhance regeneration in the presence of pro-
gressing disease of a complex nature has been addressed
using animal models of liver disease discussed above. Here
as well, HGF has shown potential as a therapeutic agent
when administered in a prophylactic manner. HGF pretreat-
ment has been shown to suppress the onset of severe hepatic
injury induced by a variety of agents, including interferon-
a, a-naphtylisothiocynate, D-gal and CCl4 [31,112–114].
Moreover, HGF-induced anti-apoptotic functions, such as
Bcl-xL discussed above, appear to have a significant role in
the prevention of FHF [108]. Treatment of mice with HGF
prior to and during induction of FHF, triggered either by
administration of Fas agonist or by LPS treatment of D-gal-
sensitized mice, which leads to the demise of the animal
typically occurring within 4 to 20 h following treatment,
maintained parenchyma integrity and dramatically increased
survival of between 80% and 100% of HGF-treated animals,
compared to 0–20% in controls, depending upon the
experimental conditions [108,115]. Similar results were
observed using an adenoviral vector-based gene therapy
approach to HGF delivery, and treatment of D-gal/LPS-
induced liver failure has also been observed, although with
no clear benefit over a protein delivery-based strategy [116].
In addition, whether HGF treatment will be effective when
initiated following the induction of liver damage is not clear
from these studies.
IL-6 does not act as a complete mitogen and does not
induce hepatocyte replication when injected to mice or rats,
but rather, as noted above, appears to mediate both priming
and cytoprotective functions at the start of liver regeneration
[65]. We have hypothesized that enhanced IL-6-mediated
priming of hepatocyte replication can cooperate with the
naturally elevated levels of endogenous HGF and other
growth factors observed during both experimentally induced
liver regeneration [60] and in FHF patients [117,118], and
can serve as a therapeutic strategy for the treatment of FHF.
To test this hypothesis, we have studied the therapeutic
efficacy of the IL-6/sIL-6R fusion protein, hyper-IL-6
administered to rats in which liver damage had been induced
7 h earlier by D-gal treatment [103]. The effect of D-gal is
rapid, and liver damage of both an apoptotic and necrotic
nature is clearly manifested by the appearance of elevated
serum biochemical parameters within several hours follow-
ing administration, which progresses to the demise of the
animal within several days (E.G., unpublished results, and
Refs. [29,119]). Treatment with hyper-IL-6, 7 h following D-
gal administration, in contrast to treatment with 10-fold
higher levels of human IL-6, or with physiological saline,
abrogated the progression of liver damage, as indicated by
the maintenance of serum ALT and bilirubin at nearly
normal levels. Hyper-IL-6 treatment also maintained hepatic
morphology and function, as indicated by maintenance of
homeostatic levels of blood clotting factors V and VII and
the absence of hypoglycemia. Moreover, survival of animals
administered with a lethal dose of D-gal was substantially
improved following hyper-IL-6 treatment. The physiologi-
cal basis for the therapeutic effect of hyper-IL-6 could be
seen both at the level of enhanced hepatocyte replication,
and by an apparent inhibition of apoptotic functions. Fol-
lowing induction of liver damage, more than 40% of
hepatocytes in hyper-IL-6-treated animals, vs. less than
5% in controls, had entered the S-phase of the cell cycle
as measured by BrdU incorporation. Correspondingly, the
abundance of apoptotic nuclei observed in IL-6-treated
animals was far greater than in hyper-IL-6-treated animals
(f 80% vs. f 20%, respectively). This clear difference in
the therapeutic efficacy of hyper-IL-6 compared to IL-6 can
be attributed both to the longer serum half-life of the fusion
protein, and also to a longer-lasting, cellular response
resulting, in part, from slower receptor complex internal-
ization [105].
E. Galun, J.H. Axelrod / Biochimica et Biophysica Acta 1592 (2002) 345–358 355
In more recent studies, we have also explored the
potential of an adenoviral-based gene therapy strategy for
the delivery of hyper-IL-6 in the treatment of FHF [23]. A
gene therapy-based strategy has the potential advantage of
increasing the local levels of a therapeutic protein by tissue
targeting, such as the hepatic targeting of systemically
delivered adenoviral vectors [120,121]. Similar to hyper-
IL-6 protein therapy, a single low dose of a hyper-IL-6
encoding adenoviral vector, in contrast to an adeno-IL-6
vector, prevented the progression of liver necrosis, induced
liver regeneration and maintained liver function in D-gal-
treated mice, leading to dramatically enhanced survival
(92–96% vs. 13–20% in control treated animals). This
study demonstrated that a liver-targeted gene therapy strat-
egy could be used to successfully treat liver failure despite
the presence of progressing liver injury. Does gene therapy
have a potential advantage in the treatment of FHF? In
studying this question, we have observed that, in contrast to
administration of hyper-IL-6 protein or control adenoviral
vectors, treatment of mice with the adeno-hyper-IL-6 vector
in the absence of liver injury induces a strong short-term
mitotic response (up to 50%) in hepatocytes (J.H.A., unpub-
lished results). This observation would suggest that, in the
context of adenoviral transduction, hyper-IL-6 acts as a
complete mitogen and may indeed have an unexpected
advantage in the treatment of FHF. Further studies are
required to understand the mechanism lying behind this
observation. These observations demonstrate that in the
presence of liver injury, IL-6-mediated stimulation of the
priming phase of hepatocyte growth and induction of anti-
apoptotic functions can provide a similar benefit to the
maintenance of liver function and recovery from cata-
strophic hepatic insult as that provided by complete mito-
gens, such as HGF.
8. Conclusions and future questions
Liver regeneration is an intricate process involving multi-
ple factors on both the cellular and molecular level. The
recent illumination of the molecular mechanisms responsi-
ble for this multifactorial process should enable us to
investigate new therapeutic avenues for treating the devas-
tating condition of FHF. The current therapies, which are
either in use or in various phases of clinical assessment, are
complicated and often expose the patient to severe adverse
effects. These include LTx, hepatocyte transplantation and
hyperfiltration systems. The wealth of knowledge recently
reported on the extracellular factors and intracellular signal-
ing cascades could suggest new therapeutic targets for FHF;
some of these biological processes are depicted in the
summary figure for this review (Fig. 1). This review
suggests assessing the potential role of natural or designer
cytokines and growth factors as potential new therapeutics.
The authors are encouraged by the survival and biochemical
results following the use of hyper-IL-6 in established FHF
animal models including mice and rats. Furthermore, a
combination of a number of cytokines and growth factors
and possibly their derivatives should also be assessed for
priming and enhancing liver regeneration. We are in an era
of translation medicine, which should include the use of
cytokine family members for specific clinical conditions;
FHF could serve as one example. Future preclinical and
possibly early clinical assessments will determine the effi-
cacy of such molecular therapy approaches.
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